je.st
news
Tag: of
Dean Foods Co (DF) Plans Quarterly Dividend of $0.07
2015-03-05 23:10:42| Food - Topix.net
Dean Foods declared a quarterly dividend on Wednesday, March 4th, Analyst Ratings Network reports. Stockholders of record on Monday, March 16th will be given a dividend of 0.07 per share on Thursday, March 26th.
The oceans may be lulling us into a false sense of climate security
2015-03-05 15:00:00| Climate Ark Climate Change & Global Warming Newsfeed
Guardian: A paper published last week in Science casts more light on oceans and how they may have contributed to a false sense of security about what we face in the future. The paper, coauthored by Byron Steinman, Michael Mann, and Sonya Miller, approached the problem in a new way that connected real-world observations with state-of-the-art climate models. What the authors find casts severe doubt on other work which had oversold the role of natural climates ability to halt global warming for the next 15 years....
LIRR delays of up to 20 minutes reported east of Jamaica
2015-03-05 13:40:02| Railroads - Topix.net
Passengers wait for an arriving train at the Hicksville Long Island Rail Road station in Hicksville, Feb. 22, 2015. Photo Credit: Steve Pfost All eastbound LIRR train lines are experiencing delays of up to 20 minutes east of Jamaica Station, Long Island Rail Road officials said, blaming a signaling problem for the rush-hour slowdown.
Tags: of
minutes
east
reported
New Perth report: We're smarter, richer and there's more of us
2015-03-05 04:27:21| Agriculture - Topix.net
Perth is the fastest growing city in Australia, dramatically outstripping other capitals according to a local think tank that has mapped the biggest contemporary changes in our identity. Its landmark report released on Thursday also found that we're getting smarter and earning more money but, our home ownership level has declined.
Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and Microtubule Dynamics Inhibitor in Multiple Types of Cancer
2015-03-05 00:30:00| Merck.com - Product News
Dateline City: TOKYO & KENILWORTH, N.J. Combination clinical studies of lenvatinib, eribulin and pembrolizumab to be explored TOKYO & KENILWORTH, N.J.--(BUSINESS WIRE)--Eisai Co., Ltd. and Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, through a subsidiary, announced today a clinical trial collaboration to evaluate the safety, tolerability and efficacy of Mercks anti-PD-1 therapy, pembrolizumab (marketed in the U.S. under the brand name KEYTRUDA), in combination with Eisai oncology compounds lenvatinib mesylate (a multi-targeting RTK inhibitor marketed in the U.S. Language: English Contact: Eisai Public Relations Department+81-(0)3-3817-5120orEisai Investor Relations+81-(0)3-3817-5327orMerck Media RelationsPamela Eisele, 267-305-3558or Claire Mulhearn, 908-236-1118orMerck Investor RelationsJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [709] [710] [711] [712] [713] [714] [715] [716] [717] [718] [719] [720] [721] [722] [723] [724] [725] [726] [727] [728] next »